TheraRadar
← Back
Data updated: Mar 29, 2026

TWI PHARMS

CardiovascularImmunologyRespiratory
Big Pharma

TWI PHARMS is a major pharmaceutical company focused on Cardiovascular, Immunology, Respiratory. Key products include FORFIVO XL.

1981
Since
29
Drugs
-
Trials
415
Approved (2yr)

Key Drugs

FENOFIBRIC ACID
choline fenofibrate
Metabolic
PPAR alpha 2 indications · 2013
FORFIVO XL
bupropion hydrochloride
CNS
Dopamine transporter 1 indications · 2011

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 58%
7 drugs
Immunology 33%
4 drugs
Respiratory 8%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular, Immunology, Respiratory
AstraZeneca big-pharma
Respiratory, Cardiovascular, Immunology
Boehringer Ingelheim big-pharma
Respiratory, Immunology, Cardiovascular
Merck big-pharma
Cardiovascular, Immunology
CHATTEM SANOFI big-pharma
Respiratory, Cardiovascular, Immunology